Pembrolizumab (Keytruda®) for persistent, recurrent or metastatic cervical cancer. HTA ID: 22041

Assessment Status Rapid Review Complete
HTA ID 22041
Drug Pembrolizumab
Brand Keytruda®
Indication Is indicated in combination with chemotherapy with or without bevacizumab, for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD-L1 with a CPS ≥1.
Assessment Process
Rapid review commissioned 16/06/2022
Rapid review completed 06/07/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard-of-care.

The company has not submitted a HTA dossier to the NCPE, therefore the cost effectiveness of the technology could not be proven.